IBD Evidence

Treatment

Biologics and advanced therapies compared

For the first time, the comparative question — which drug, not whether a drug — has meta-analytic answers.

Updated 2 min read 26 citations Evidence strength 5/5

Wire endoscopy snare used for upper gastrointestinal and colonic polypectomy
Gilo1969 · CC BY-SA 3.0 · Wikimedia Commons

What changed

For two decades the evidence base was drug-versus-placebo, which told clinicians that biologics work and nothing about which to choose. Network meta-analysis has changed that by using shared comparators to rank therapies indirectly [1][4].

The practical consequence is that first-line choice can now be reasoned about rather than defaulted, and differences between agents on induction versus maintenance, and on efficacy versus safety, are visible.

Comparative efficacy of advanced therapies

The classes

Advanced therapy classes in IBD
ClassMechanismNotes
Anti-TNFBlocks tumour necrosis factor alphaLongest track record; immunogenicity is the main limitation
Anti-integrinBlocks leucocyte trafficking to the gutGut-selective, so favourable systemic safety
Anti-IL-12/23 and anti-IL-23Blocks interleukin signallingStrong efficacy and safety profile in recent comparisons
JAK inhibitorsSmall molecule, intracellular signallingOral and rapid; cardiovascular and thrombosis warnings
S1P modulatorsSequesters lymphocytes in lymph nodesOral; newer, less long-term data

Treat to target, not to symptoms

The most consequential shift in IBD management is that symptoms are a poor proxy for inflammation. People feel well with active inflammation and feel unwell in remission. Current European guidance therefore targets objective markers — faecal calprotectin, endoscopic healing — rather than how the patient reports feeling.

This is also the answer to the dietary question raised on the diet page: an intervention that improves symptoms without improving objective markers has not treated the disease.

When one drug is not enough

Dual biologic or combined small-molecule therapy has been assessed for refractory disease [3]. It remains a specialist decision with a limited evidence base, and it is where single-cell work characterising response heterogeneity [2] is most likely to change practice — by predicting which mechanism to target in a given patient rather than discovering it by sequential failure.

Street view of the station pharmacy building in Bautzen, Germany
Fiver, der Hellseher · CC BY-SA 4.0 · Wikimedia Commons

Common questions

Which biologic is best?
Network meta-analyses now rank them [1][4], and the right choice depends on disease location, severity, extraintestinal features and your own risk tolerance.
Can I stop once I am in remission?
Withdrawal carries substantial relapse risk. It is a decision to make with your team, based on objective markers rather than how you feel.
Are biologics dangerous?
They carry real risks, principally infection. Untreated inflammation also carries risk, and the comparison is between two risks rather than against zero.
What is calprotectin for?
A stool marker of intestinal inflammation. It is how "treat to target" is actually monitored.
The evidence behind this page A stacked bar showing the composition of the 26 publications cited on this page by study type. 26meta-analysis (26)
26 publications, 2015–2025. This is a largely observational base. It can establish that things occur together; it cannot settle which one causes the other. Source: this page’s own citation list, below.

References

Every citation below links to the original peer-reviewed record on PubMed or via DOI. Nothing here is a substitute for medical advice.

  1. Management of paediatric ulcerative colitis, part 2: Acute severe colitis-An updated evidence-based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organization Assa A, Aloi M, Van Biervliet S, et al. · Journal of pediatric gastroenterology and nutrition · 2025 · Clinical guideline DOIPubMed 40528309
  2. Management of paediatric ulcerative colitis, part 1: Ambulatory care-An updated evidence-based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organisation Wine E, Aloi M, Van Biervliet S, et al. · Journal of pediatric gastroenterology and nutrition · 2025 · Clinical guideline DOIPubMed 40677018Full text
  3. Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Crohn's Disease: 2025 AGA Evidence Synthesis Singh S, Murad MH, Yuan Y, et al. · Gastroenterology · 2025 · Meta-analysis DOIPubMed 41114682Full text
  4. ACG Clinical Guideline Update: Ulcerative Colitis in Adults Rubin DT, Ananthakrishnan AN, Siegel CA, et al. · The American journal of gastroenterology · 2025 · Clinical guideline DOIPubMed 40701556
  5. ACG Clinical Guideline: Management of Crohn's Disease in Adults Lichtenstein GR, Loftus EV, Afzali A, et al. · The American journal of gastroenterology · 2025 · Clinical guideline DOIPubMed 40701562
  6. AGA Clinical Practice Guideline on the Management of Pouchitis and Inflammatory Pouch Disorders Barnes EL, Agrawal M, Syal G, et al. · Gastroenterology · 2024 · Clinical guideline DOIPubMed 38128971Full text
  7. AGA Clinical Practice Update on Diet and Nutritional Therapies in Patients With Inflammatory Bowel Disease: Expert Review Hashash JG, Elkins J, Lewis JD, et al. · Gastroenterology · 2024 · Clinical guideline DOIPubMed 38276922
  8. Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis Ananthakrishnan AN, Murad MH, Scott FI, et al. · Gastroenterology · 2024 · Meta-analysis DOIPubMed 39425738Full text
  9. AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis Singh S, Loftus EV Jr, Limketkai BN, et al. · Gastroenterology · 2024 · Clinical guideline DOIPubMed 39572132Full text
  10. ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment Adamina M, Minozzi S, Warusavitarne J, et al. · Journal of Crohn's & colitis · 2024 · Clinical guideline DOIPubMed 38878002
  11. Single-cell meta-analysis of inflammatory bowel disease with scIBD Nie H, Lin P, Zhang Y, et al. · Nature computational science · 2023 · Meta-analysis DOIPubMed 38177426
  12. JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications Russell MD, Stovin C, Alveyn E, et al. · Annals of the rheumatic diseases · 2023 · Meta-analysis DOIPubMed 37247942Full text
  13. Altered Bioavailability and Pharmacokinetics in Crohn's Disease: Capturing Systems Parameters for PBPK to Assist with Predicting the Fate of Orally Administered Drugs Alrubia S, Mao J, Chen Y, et al. · Clinical pharmacokinetics · 2022 · Meta-analysis DOIPubMed 36056298Full text
  14. Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis Ahmed W, Galati J, Kumar A, et al. · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022 · Meta-analysis DOIPubMed 33798711
  15. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis Lasa JS, Olivera PA, Danese S, et al. · The lancet. Gastroenterology & hepatology · 2022 · Meta-analysis DOIPubMed 34856198
  16. Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials Ben-Horin S, Novack L, Mao R, et al. · Gastroenterology · 2022 · Meta-analysis DOIPubMed 34757139
  17. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis Peyrin-Biroulet L, Arkkila P, Armuzzi A, et al. · BMC gastroenterology · 2022 · Meta-analysis DOIPubMed 35676620Full text
  18. [ESPEN guideline: Clinical nutrition in inflammatory bowel disease] Bischoff SC, Escher J, Hébuterne X, et al. · Nutricion hospitalaria · 2022 · Clinical guideline DOIPubMed 35014851
  19. Long-term dietary patterns are associated with pro-inflammatory and anti-inflammatory features of the gut microbiome Bolte LA, Vich Vila A, Imhann F, et al. · Gut · 2021 · Meta-analysis DOIPubMed 33811041Full text
  20. Ulcerative Colitis-Diagnostic and Therapeutic Algorithms Kucharzik T, Koletzko S, Kannengiesser K, et al. · Deutsches Arzteblatt international · 2020 · Meta-analysis DOIPubMed 33148393Full text
  21. The association between endometriosis and autoimmune diseases: a systematic review and meta-analysis Shigesi N, Kvaskoff M, Kirtley S, et al. · Human reproduction update · 2019 · Meta-analysis DOIPubMed 31260048Full text
  22. ACG Clinical Guideline: Ulcerative Colitis in Adults Rubin DT, Ananthakrishnan AN, Siegel CA, et al. · The American journal of gastroenterology · 2019 · Clinical guideline DOIPubMed 30840605
  23. ACG Clinical Guideline: Management of Crohn's Disease in Adults Lichtenstein GR, Loftus EV, Isaacs KL, et al. · The American journal of gastroenterology · 2018 · Clinical guideline DOIPubMed 29610508
  24. Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care-An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition Turner D, Ruemmele FM, Orlanski-Meyer E, et al. · Journal of pediatric gastroenterology and nutrition · 2018 · Clinical guideline DOIPubMed 30044357
  25. Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease de Lange KM, Moutsianas L, Lee JC, et al. · Nature genetics · 2017 · Meta-analysis DOIPubMed 28067908Full text
  26. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations Liu JZ, van Sommeren S, Huang H, et al. · Nature genetics · 2015 · Meta-analysis DOIPubMed 26192919Full text